// changes done below on July 01 2024 // till here on July 01 2024

The ADC Cytotoxic Payloads / Warheads market is anticipated to grow at a CAGR of 12.4% till 2030, claims Roots Analysis

Published: April 2022

With six approved drugs, namely POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA®, ADCETRIS® and over 300 drugs underdevelopment, antibody drug conjugates (ADCs) have emerged as a promising class of targeted therapies for various disease indications


Roots Analysis has announced the addition of “ADC Cytotoxic Payloads / Warheads: Products and Services Market, 2021-2030” report to its list of offerings.

Given the fact that ADCs are highly potent cytotoxic molecules, the manufacturing of ADCs requires elaborate and advanced technical capabilities and highly potent chemical substances. Specifically, the multi-step process of production of cytotoxic payloads, which are complex structures used in ADCs, requires a specially designed and contained environment, dedicated manufacturing facilities, specialized analytical and purification techniques, and storage facilities.

To order this 130+ page report, which features 50+ figures and 15+ tables, please visit 

Key Market Insights

Over 40 companies claim to offer ADC cytotoxic payloads / warheads for ADCs
Presently, the market is dominated by the presence of large (501-10,000 employees) and mid-sized companies ( 51-500 employees). It is worth noting that majority (44%) of the firms engaged in this domain are based in Europe, followed by North America (28%) and Asia Pacific (28%).

More than 430 patents related to ADC cytotoxic payloads / warheads have been granted / filed between 2016-2021
A significant increase has been observed in the number of patent applications filed over the last few years. Majority (80%) of the patents were filed / granted in North America; other key regions with significant intellectual capital include regions of Europe and South Korea

Close to 40 partnerships have been inked among various industry and non-industry players between 2016 and 2021
Maximum number of partnerships were established in 2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that, majority of the deals were licensing agreements, representing over 35% of the total number of partnerships signed in the given time period.

Close to USD 1,100 million has been invested by both private and public investors, since 2016
Of the total amount invested, over USD 719 million was raised through venture capital financing, representing over 42% of the overall funding activity in this domain. Further, 5 instances of private placements were also reported, wherein players collectively raised more than USD 190 million.

North America and Europe are anticipated to capture larger share of the market share by 2030
Growth in this domain is anticipated to be primarily driven by the demand of auristatins and maytansinoids payloads. It is worth mentioning that ADC cytotoxic payloads / warheads market for microtubule inhibitors is likely to capture nearly 40% of the total market share by 2030.

To request a sample copy / brochure of this report, please visit 

Key Questions Answered
  • Who are the leading players engaged in the development of ADC cytotoxic payloads / warheads?
  • What kind of partnership models are commonly adopted by industry stakeholders engaged in the ADC cytotoxic payloads / warheads domain?
  • Which key investors are likely to drive the development efforts related to ADC cytotoxic payloads / warheads? 
  • How has the intellectual property landscape of ADC cytotoxic payloads / warheads evolved over the years?
  • How is the current and future opportunity likely to be distributed across key market segments?     

The financial opportunity within the ADC cytotoxic payloads / warheads market has been analyzed across the following segments:

  • Type of Payload
  • Microtubule Inhibitors
  • DNA Damaging Agents
  • Topoisomerase Inhibitors 
  • Payload
  • Auristatins
  • Camptothecin
  • Maytansinoids
  • Type of Product
  • Commercialized Products
  • Clinical Products
  • Key Geographical Regions 
  • North America
  • Europe
  • Asia Pacific

The report features inputs from eminent industry stakeholder(s), who were very optimistic concerning the growth of the ADC cytotoxic payloads / warheads market. It includes detailed transcripts of the discussions held with the senior representatives of the stakeholder firms.

The report also includes detailed profiles of the companies (listed below) engaged in developing ADC cytotoxic payloads / warheads; each profile features an overview of the company, its financial information (if available), details on its product portfolio, recent developments, and an informed future outlook.

  • Abzena
  • Levana Biopharma
  • MabPlex
  • NJ Bio
  • Novasep
  • STA Pharmaceuticals
  • Synaffix

For additional details, please visit 
https://www.rootsanalysis.com/reports/adc-cytotoxic-payloads-market.html or email sales@rootsanalysis.com 

You may also be interested in the following titles: 
1.    Antibody Drug Conjugates Market, 2021-2030
2.    Biologics Fill / Finish Services Market, 2021-2030
3.    Global Antibody Purification Services Market,  2021-2030

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry